1. Scrip

Sarepta CEO Vows To Get Exondys 51 Into EU Despite CHMP Negative Trend Vote

 
• By Sten Stovall

CEO Doug Ingram aims to change EMA panel's view with a re-review, but concedes that EU arrival of the controversial DMD drug will now take longer than first thought.

DMD
Sarepta’s DMD Drug Eteplirsen Has Been Rebuffed By European Regulatory Advisors • Source: Shutterstock

Sarepta Therapeutics Inc.’s plans to get its drug Exondys 51 (eteplirsen) approved in Europe this year have been derailed by regulatory advisors there, but the Boston, Mass.-based biotech's CEO has vowed to do what it takes to get the proposed treatment for Duchenne muscular dystrophy (DMD) re-assessed - and ultimately launched - on the European market.

Sarepta used its first-quarter earnings update on May 3 to announce that it received a negative trend vote following its oral presentation to the European Medicines Agency panel, the Committee for Medicinal Products for Human

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.